Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK health agency merger

This article was originally published in The Tan Sheet

Executive Summary

Medicines Control Agency, Medical Devices Agency will merge into single, as-yet-unnamed entity next April due to increasing convergence in drug, medical device fields, Department of Health announces June 13. Systems and processes by which drugs are licensed, medical devices are controlled will not be affected, but merger will include creation of chairman post to serve as agency's authoritative figurehead and oversee strategic management. Agency also will have a chief executive; current MCA Chief Exec Keith Jones, MD, is leaving his post in October...

You may also be interested in...

UK health agency

Medicines & Healthcare Products Regulatory Agency will become official April 1 with new Web site at MHRA will consist of Medicines Control Agency and Medical Devices Agency; merger was initiated in June 2002 to address convergence of drug, medical device fields (1"The Tan Sheet" June 17, 2002, In Brief)...

UK medicines agency head

Alasdair Breckenridge, chairman of the Medicines Control Agency's Committee on the Safety of Medicines, named chair-designate of UK's Medicines & Healthcare Products Regulatory Agency, Department of Health announces Nov. 28. MHRA will consist of MCA and Medical Devices Agency and will become official in April 2003 (1"The Tan Sheet" June 17, 2002, In Brief). One of Breckenridge's first responsibilities will be to help appoint a chief exec of MHRA; last day to submit applications for the post was Nov. 20...

‘Supplement’ On CBD Product Label A Bullseye For US Litigants, Says Attorney

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts